Roche, Chugai license Xencor's XmAb to enhance antibodies
Xencor (engineering antibodies to treat cancer, inflammation, and autoimmune diseases) has licensed Roche and its Japanese affiliate Chugai Pharmaceutical Co. Ltd. individual rights to use its flagship XmAb optimization technology for one year to enhance antibodies against undisclosed cancer targets.
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.